0000000000380443

AUTHOR

Michael Hundemer

showing 5 related works from this author

Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

2019

All authors: Andrea Cossarizza Hyun‐Dong Chang Andreas Radbruch Andreas Acs Dieter Adam Sabine Adam‐Klages William W. Agace Nima Aghaeepour Mübeccel Akdis Matthieu Allez Larissa Nogueira Almeida Giorgia Alvisi Graham Anderson Immanuel Andrä Francesco Annunziato Achille Anselmo Petra Bacher Cosima T. Baldari Sudipto Bari Vincenzo Barnaba Joana Barros‐Martins Luca Battistini Wolfgang Bauer Sabine Baumgart Nicole Baumgarth Dirk Baumjohann Bianka Baying Mary Bebawy Burkhard Becher Wolfgang Beisker Vladimir Benes Rudi Beyaert Alfonso Blanco Dominic A. Boardman Christian Bogdan Jessica G. Borger Giovanna Borsellino Philip E. Boulais Jolene A. Bradford Dirk Brenner Ryan R. Brinkman Anna E. S. Broo…

0301 basic medicineConsensusImmunologyConsensuCell SeparationBiologyArticleFlow cytometry03 medical and health sciences0302 clinical medicineGuidelines ; Immunology ; Flow cytometryAllergy and ImmunologymedicineCell separationImmunology and AllergyHumansguidelines; flow cytometry; immunologymedicine.diagnostic_testBIOMEDICINE AND HEALTHCARE. Basic Medical Sciences.Cell sortingFlow CytometryCell selectionData science3. Good health030104 developmental biologyPhenotypeAllergy and Immunology; Cell Separation; Consensus; Flow Cytometry; Humans; Phenotype[SDV.IMM]Life Sciences [q-bio]/ImmunologyBIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti.030215 immunologyHumanEuropean journal of immunology
researchProduct

Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletion.

2013

Tumor-growth is often associated with the expansion of myeloid derived suppressor cells that lead to local or systemic arginine depletion via the enzyme arginase. It is generally assumed that this arginine deficiency induces a global shut-down of T cell activation with ensuing tumor immune escape. While the impact of arginine depletion on polyclonal T cell proliferation and cytokine secretion is well documented, its influence on chemotaxis, cytotoxicity and antigen specific activation of human T cells has not been demonstrated so far. We show here that chemotaxis and early calcium signaling of human T cells are unimpaired in the absence of arginine. We then analyzed CD8(+) T cell activation…

Cytotoxicity Immunologiclcsh:MedicineCD8-Positive T-LymphocytesARGINASELymphocyte ActivationGranzymesInterleukin 21Cytotoxic T cellIL-2 receptorlcsh:ScienceCells CulturedMultidisciplinarybiologyT CellsChemotaxisVaccinationCOFILINCD28Natural killer T cellCANCERmedicine.anatomical_structureMedicineScience & Technology - Other TopicsImmunotherapyResearch ArticleTumor ImmunologyEXPRESSIONINFILTRATING LYMPHOCYTESCARCINOMAGeneral Science & TechnologyT cellImmune CellsImmunologyArginineImmune SuppressionDENDRITIC CELLSImmunomodulationInterferon-gammaMART-1 AntigenMULTIPLE-MYELOMAMD MultidisciplinarymedicineImmune ToleranceHumansCalcium SignalingAntigen-presenting cellBiologyCell ProliferationCD40Science & TechnologyMULTIDISCIPLINARY SCIENCESPerforinlcsh:RImmunityImmunoregulationIN-VITROImmunologic SubspecialtiesMolecular biologybiology.proteinMYELOID SUPPRESSOR-CELLSClinical ImmunologyTumor Escapelcsh:QT-Lymphocytes CytotoxicPLoS ONE
researchProduct

Δ133p53α enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity

2021

BackgroundTumor microenvironment-associated T cell senescence is a key limiting factor for durable effective cancer immunotherapy. A few studies have demonstrated the critical role of the tumor suppressor TP53-derived p53 isoforms in cellular senescence process of non-immune cells. However, their role in lymphocytes, in particular tumor-antigen (TA) specific T cells remain largely unexplored.MethodsHuman T cells from peripheral blood were retrovirally engineered to coexpress a TA-specific T cell receptor and the Δ133p53α-isoform, and characterized for their cellular phenotype, metabolic profile and effector functions.ResultsPhenotypic analysis of Δ133p53α-modified T cells revealed a marked …

0301 basic medicineMaleCancer Researchmedicine.medical_treatmentT cellT-LymphocytesImmunologyReceptors Antigen T-Cell2436receptorsBiologycell engineeringadoptive03 medical and health sciencesMice0302 clinical medicineantigenTIGITCancer immunotherapyAntigenCell Line TumorNeoplasmsmedicineTumor MicroenvironmentImmunology and AllergyAnimalsHumans1506RC254-282PharmacologyImmune Cell Therapies and Immune Cell EngineeringCD28Neoplasms. Tumors. Oncology. Including cancer and carcinogensT lymphocyteImmunotherapycostimulatory and inhibitory T-cell receptorsCell biology030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisMolecular MedicineimmunotherapyCD8Journal for ImmunoTherapy of Cancer
researchProduct

The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma

2018

Purpose: While recent studies described the role of IKZF1/3 proteins in multiple myeloma (MM) cells, few have highlighted the significance of IKZF1/3 expression in T-cells. In this study we examine the prognostic and predictive value of IKZF1/3 expression in T-cells in patients with MM stage III. Experimental design: We analysed the IKZF1/3 expression levels in T-cells from 45 MM stage I (MMI) and 50 newly diagnosed MM stage III (MMIII) patients, according to Durie-Salmon staging system, by flow cytometry to examine their prognostic and predictive value. We also combined in vivo observations with in vitro assays to determine the effect of IKZF1/3 expression on the T-cell immunophenotype and…

lcsh:Immunologic diseases. Allergy0301 basic medicineOncologymedicine.medical_specialtyImmunologyMedizinlcsh:RC254-282Flow cytometry03 medical and health sciencesikzf10302 clinical medicineImmunophenotypingikzf3immunomodulatory drugsIn vivoInternal medicinemedicineImmunology and AllergyStage (cooking)t cellsMultiple myelomaOriginal ResearchLenalidomidemedicine.diagnostic_testbusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePomalidomidemultiple myelomaThalidomide030104 developmental biologyOncologybiomarker trialsimmunelcsh:RC581-607business030215 immunologymedicine.drug
researchProduct

Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL.

2005

Abstract Growing evidence indicates that multiple myeloma (MM) and other malignancies are susceptible to CTL-based immune interventions. We studied whether transcription factors inherently involved in the terminal differentiation of mature B lymphocytes into malignant and nonmalignant plasma cells provide MM-associated CTL epitopes. HLA-A*0201 (A2.1) transgenic mice were used to identify A2.1-presented peptide Ag derived from the plasma cell-associated transcriptional regulators, positive regulatory domain I-binding factor 1 (PRDI-BF1) and X box-binding protein 1 (XBP-1). A2.1-restricted CTL specific for PRDI-BF1 and XBP-1 epitopes efficiently killed a variety of MM targets. PRDI-BF1- and X…

Cytotoxicity ImmunologicX-Box Binding Protein 1Cellular differentiationImmunologyEpitopes T-LymphocyteMice TransgenicRegulatory Factor X Transcription FactorsBiologyEpitopeMiceImmune systemCell Line TumorHLA-A2 AntigenImmunology and AllergyAnimalsHumansTranscription factorAntigen PresentationB-LymphocytesCell DeathT-cell receptorCell DifferentiationCytotoxicity Tests ImmunologicX-Box Binding Protein 1Molecular biologyPeptide FragmentsCell biologyDNA-Binding ProteinsMice Inbred C57BLRepressor ProteinsCTL*Self ToleranceNIH 3T3 CellsPositive Regulatory Domain I-Binding Factor 1Multiple MyelomaCD8T-Lymphocytes CytotoxicTranscription FactorsJournal of immunology (Baltimore, Md. : 1950)
researchProduct